## INCY: Incyte Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.12 indicates fundamental undervaluation. Quality metrics strong (ROE 30%, ROA 14%). Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($91.17)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. Incyte Announces European Commission Approval of MinjuviÂ® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma**
- Source: Business Wire | 20251217T160754 | Bullish | Relevance: 100%
- Incyte announced that the European Commission has approved Minjuvi (tafasitamab) in combination with lenalidomide and rituximab for adult patients with relapsed or refractory follicular lymphoma (FL). This first-of-its-kind chemotherapy-free dual-targeted immunotherapy offers a new treatment option for eligible patients. The approval is based on Phase 3 inMIND trial data demonstrating significantly improved progression-free survival compared to placebo.

**2. Incyte Corp. stock outperforms competitors on strong trading day**
- Source: MarketWatch | 20251215T163000 | Bullish | Relevance: 100%
- Incyte Corp. (INCY) shares rose 3.39% to $98.64 on a challenging trading day, outperforming the S&P 500 and Dow Jones Industrial Average which experienced slight declines. Despite the gain, Incyte Corp. closed 9.73% below its 52-week high of $109.28 reached on November 12th. The article highlights Incyte's strong performance relative to the broader market.

**3. Is Incyte Stock Outperforming the Nasdaq?**
- Source: Palmetto Grain Brokerage | 20251215T072100 | Bullish | Relevance: 100%
- Incyte Corporation (INCY) has demonstrated strong stock performance, outperforming the Nasdaq Composite (NASX) across various timeframes, including the past three months, year-to-date, and the past 52 weeks. The company reported better-than-expected Q3 2025 results with increased revenue and raised full-year guidance, although the stock saw a slight dip on the announcement day. Analysts maintain a "Moderate Buy" rating for INCY, with a mean price target suggesting an upside to current levels.

**4. Incyte Says European Commission Approves Minjuvi Combination Therapy for Follicular Lymphoma**
- Source: marketscreener.com | 20251217T170810 | Bullish | Relevance: 100%
- Incyte announced that the European Commission has approved Minjuvi (tafasitamab) in combination with lenalidomide for adult patients with relapsed or refractory follicular lymphoma (FL) who are not candidates for hematopoietic stem cell transplant. This approval marks a significant step for patients in Europe battling this type of blood cancer, offering a new treatment option. The news follows earlier reports of Incyte presenting data at ESMO Congress 2025 and obtaining FDA Breakthrough designation for other pipeline candidates.

**5. Incyte wins EU approval of Xencor-partnered lymphoma drug**
- Source: Seeking Alpha | 20251217T165416 | Bullish | Relevance: 100%
- Incyte announced that the European Commission has approved a drug regimen including its Xencor-partnered antibody drug Minjuvi. This treatment, also known as tafasitamab, is approved as a late-line option for certain adult patients with follicular lymphoma, a type of blood cancer. The drug will now be available in the EU.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Morgan Stanley | $92 | $86 | +7% |
| 2025-12-08 | Wells Fargo | $116 | $97 | +20% |
| 2025-12-08 | Mizuho | $121 | $90 | +34% |
| 2025-11-24 | Barclays | $115 | $101 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Morgan Stanley | main | Equal-Weight |
| 2025-12-08 | Wells Fargo | main | Overweight |
| 2025-12-08 | Mizuho | up | Outperform |
| 2025-11-24 | Barclays | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 6 ($0.08M) |
| Sells | 17 ($23.81M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 59.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Baker Bros. Advisors: 15.7% (0.0%)
- Vanguard Group Inc: 10.2% (-0.9%)
- Blackrock Inc.: 9.1% (-0.3%)
- Dodge & Cox Inc.: 7.1% (-4.5%)
- State Street Corpora: 4.9% (-2.0%)

### Key Risks

1. Heavy insider selling: $24M sold (17 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +19%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.12 indicates undervaluation relative to growth. Forward P/E 12.7x attractive for 13% earnings growth. Quality metrics strong (ROE 30%, ROA 14%, margin 25%). Balance sheet: strong liquidity (3.2x), low leverage (D/E 0.36). Analyst sentiment positive (4 raises, avg +19%). Insider selling cluster ($23.8M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.2B |
| Beta | 0.81 |
| 52W Range | $53.56 - $109.28 |
| Short Interest | 6.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.12 |
| Forward P/E | 12.7 |
| Current P/E | 14.3 |
| YoY Growth | 12.7% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from -7.7% to -0.8% (+6.9% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.8pp (needs >4.0% for momentum thesis). MRS_5 turning positive (2.6%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.26x) but short-term weakness (below SMA20). MACD histogram bearish (-0.76), momentum weakening. RSI neutral at 46. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.79% (CS: 25) | Neutral |
| RSI_14 | 46.5 | Neutral |
| MACD Histogram | -0.76 | Bearish |
| vs SMA20 | 0.973x | Below |
| vs SMA50 | 1.005x | Above |
| vs SMA200 | 1.259x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $97.63
- **Stop Loss:** $91.17 (6.6% risk)
- **Target:** $110.55 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 167
- **Position Value:** $16,304.21
- **Portfolio %:** 16.30%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-09 (Est: $1.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.64 | $2.26 | +38.0% |
| 2025Q2 | $1.47 | $1.57 | +6.6% |
| 2025Q1 | $1.03 | $1.16 | +12.3% |
| 2024Q4 | $1.55 | $1.43 | -8.0% |

---
*RULE-based L3 | 2026-01-07 01:41 | MRS_20*